Intelligence Report · ~15 min read
Nutritional Deficiency · Vitamin B12 Therapeutic Area Assessment
1 signals · 1 insights · 5 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 60%
Evidence
7 items
Sources
1
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Nutritional Deficiency · Vitamin B12 integrates 1 signals, 1 executive insights, and 5 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 15, 2026
FDA Grants Approval for Cyancobalamin ANDA219820 by Aspiro
The FDA has granted approval for the ANDA219820 application for Cyancobalamin submitted by Aspiro.
View detail - regulatoryJul 15, 2026
Ongoing | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
View detail - regulatoryJul 15, 2026
CDER proposes to withdraw approval of TAVNEOS
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Aspiro; the same agency is already in play for this signal, so precedent weight is higher.
View detail - regulatoryJul 15, 2026
Withdrawn | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
View detail - regulatoryJul 15, 2026
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
View detail - insightJul 15, 2026
Aspiro's Cyancobalamin Approval Enhances Competitive Position in Vitamin B12 Market
The FDA's approval of Aspiro's Cyancobalamin ANDA219820 is significant as it strengthens Aspiro's position in the competitive Vitamin B12 supplement market. This development necessitates close monitoring of market dynamics and competitor responses to assess potential impacts on market share and positioning. Regulatory context from FDA (Rare Disease Drug Approvals) supports the near-term read. Assessment grounded in 15 ranked evidence items (5 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 5 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Ongoing | Cancer Accelerated Approvals
66%This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Source: FDA
View evidenceCDER proposes to withdraw approval of TAVNEOS
84%Why this matters: illustrates how regulators handled a comparable approval decision relevant to Aspiro; the same agency is already in play for this signal, so precedent weight is higher.
Source: FDA
View evidenceWithdrawn | Cancer Accelerated Approvals
84%This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
Source: FDA
View evidenceOncology (Cancer)/Hematologic Malignancies Approval Notifications
84%FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Source: FDA
View evidenceFDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
84%Why this matters: illustrates how regulators handled a comparable approval decision relevant to Aspiro; the same agency is already in play for this signal, so precedent weight is higher.
Source: FDA
View evidenceAspiro's Cyancobalamin Approval Enhances Competitive Position in Vitamin B12 Market
60%The FDA's approval of Aspiro's Cyancobalamin ANDA219820 is significant as it strengthens Aspiro's position in the competitive Vitamin B12 supplement market. This development necessitates close monitoring of market dynamics and competitor responses to assess potential impacts on market share and positioning. Regulatory context from FDA (Rare Disease Drug Approvals) supports the near-term read. Assessment grounded in 15 ranked evidence items (5 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Grants Approval for Cyancobalamin ANDA219820 by Aspiro
Regulatory Approval
Insights
- Aspiro's Cyancobalamin Approval Enhances Competitive Position in Vitamin B12 Market
Nutritional Deficiency · Vitamin B12